The Labs Your Doctor Didn't Run (Pre-Protocol Bloodwork Blueprint)

Most men who get their testosterone checked walk away with a single number and a "you're fine." And that number, taken alone, tells you almost nothing about what your hormonal system is actually doing.

Here is why that matters, and what a complete picture actually looks like.

Your body produces testosterone in a chain that starts in the brain. The hypothalamus sends a signal called GnRH, which triggers the pituitary gland to release two hormones called LH and FSH, which then travel down to the testes and tell them to produce testosterone. The testosterone that gets made then circulates in the blood, but not all of it is available to your cells. Some of it gets bound up by a protein called SHBG, which stands for sex hormone binding globulin, and when testosterone is bound to SHBG it cannot dock with receptors in muscle, brain, bone, or anywhere else. Only the unbound portion, called free testosterone, is biologically active.

That is the whole chain. And when your doctor only checks total testosterone, they are looking at one output in the middle of that chain without checking anything upstream or downstream.

The upstream problem is why LH and FSH matter so much. If your total testosterone comes back low, there are two completely different reasons that could be true. Either your brain is not sending the signal correctly, a condition called secondary hypogonadism, or your testes are receiving the signal but failing to respond, which is called primary hypogonadism. The Endocrine Society's 2018 clinical guidelines specifically state that LH and FSH are needed to make this distinction, and the distinction changes everything about how you approach treatment. A man whose pituitary is underperforming may respond to a different intervention entirely than a man whose testes themselves are the problem. Without LH and FSH, you are guessing.

The downstream problem is why SHBG changes the meaning of total testosterone so dramatically. A man with a total testosterone of 600 ng/dL but very high SHBG may have less free testosterone than a man sitting at 400 ng/dL with low SHBG. The harmonized reference data from a 2017 study of over 9,000 men set the normal range at 264 to 916 ng/dL, which is a wide window, and whether someone is functioning well at any given number within that window depends heavily on how much of that testosterone is actually free.

Estradiol belongs in this panel too, and measuring it correctly requires something called LC-MS/MS, which is a liquid chromatography method that is significantly more accurate than the standard immunoassay used by most commercial labs. Research from 2013 published in the Journal of Clinical Endocrinology and Metabolism showed that standard immunoassays produce unreliable estradiol measurements in men, which matters because estradiol affects libido, bone density, mood, and cardiovascular function, and you need an accurate number before you can make any decisions about managing it.

Prolactin and DHEA-S round out the hormonal picture. Elevated prolactin can suppress the entire hypothalamic-pituitary axis and is one of the most commonly missed reasons for low testosterone, since it often has a correctable cause. DHEA-S is a precursor hormone that declines with age and interacts with the broader hormonal environment in ways that matter when you are designing a protocol.

On the metabolic side, the standard glucose test in a basic metabolic panel misses something important. You can have a completely normal fasting glucose while your pancreas is working three times as hard to keep it there, and that elevated workload is called insulin resistance, which is the early stage of a process that eventually leads to type 2 diabetes. The only way to see it before blood sugar starts rising is to measure fasting insulin directly. Hemoglobin A1c adds another layer by showing your average blood glucose over the prior two to three months rather than a single snapshot.

For cardiovascular risk, standard lipid panels report total cholesterol, LDL, HDL, and triglycerides, and those numbers describe concentration. But what actually drives arterial plaque is not just the concentration of cholesterol but the number of particles carrying it, and that is what a marker called apolipoprotein B measures. ApoB reflects the total count of atherogenic particles in circulation, and research has consistently shown it to be a stronger predictor of cardiovascular events than LDL cholesterol alone. High sensitivity C-reactive protein tells you whether there is active low-grade inflammation in the vascular system, which independently predicts cardiovascular risk beyond what the lipid numbers show.

The safety markers matter for a different reason, which is that starting a protocol without them means you have no baseline to compare against later. Hematocrit, which is the percentage of your blood volume made up of red blood cells, is something testosterone directly elevates because testosterone stimulates red blood cell production in the bone marrow. A 2022 study in the Journal of Urology found that men on testosterone therapy with a hematocrit at or above 52 percent had a 35 percent higher risk of major cardiovascular events and blood clots compared to men with lower hematocrit. That is not a theoretical risk. It is the reason hematocrit monitoring is standard protocol during TRT, and it is why you need a baseline before you start.

IGF-1, which is a growth factor that reflects how active your growth hormone axis is, matters specifically if you are considering peptide therapy. Without a pre-treatment measurement you cannot determine whether the intervention is doing anything.

Thyroid function connects to nearly every symptom that overlaps with low testosterone: fatigue, poor body composition, slow recovery, low libido. TSH alone is not enough because it only reflects the pituitary's demand signal, not how much active thyroid hormone is actually circulating. Free T3 and free T4 tell you what is available at the tissue level.

The point of running all of this before starting anything is not complexity for its own sake. It is that any protocol is only as good as the information it is built on, and symptoms without context lead to interventions without precision.

A number without a system behind it is just a number.

---

References

1. Bhasin S et al. Testosterone Therapy in Men With Hypogonadism. JCEM. 2018 — Endocrine Society guideline: diagnosis requires two fasting morning total T measurements, distinguish primary vs secondary via LH/FSH
2. Mulhall JP et al. Evaluation and Management of Testosterone Deficiency. AUA Guideline. J Urology. 2018 — Total T below 300 ng/dL threshold, recommend LH in all men with low T
3. Travison TG et al. Harmonized Reference Ranges for Circulating Testosterone Levels. JCEM. 2017 — 9,054 men, harmonized range 264-916 ng/dL
4. Ory J et al. Secondary Polycythemia in Men Receiving Testosterone Therapy. J Urology. 2022 — Hematocrit >=52% on TRT = 35% higher MACE/VTE risk (OR 1.35)
5. Rosner W et al. Toward Excellence in Testosterone Testing. JCEM. 2013 — Sensitive LC-MS/MS required for accurate male estradiol

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness